Lemonaid
acquired by 23andMeSan Francisco, US · 11 known investors
Lemonaid Health is a telehealth company that lets patients access medical care and treatment online from home, including services like contraceptive pill prescriptions and UTI treatment. It serves patients primarily in the United States, with a later launch in the UK.
Also known as Lemonaid Health
Founders & leadership
Investors · 11
Company profile
researched Aug 2026Lemonaid Health is a San Francisco-based national telehealth provider that lets patients complete an online health assessment, have it reviewed by a U.S.-licensed medical team, and receive prescription medication by mail. Its clinical team includes physicians, pharmacists, nurse practitioners and registered nurses licensed across all 50 states, and delivery is offered with 2-3 business day shipping in discreet packaging.
The service spans weight loss (GLP-1 medications including compounded semaglutide and tirzepatide), mental health (anxiety, depression, insomnia, seasonal affective disorder, smoking cessation), men's health (erectile dysfunction, premature ejaculation, hair loss), women's health (birth control, emergency contraception, UTI, hot flashes), general and primary care (cold sore, genital herpes, sinus infection, asthma, acid reflux, migraine, hypothyroidism), chronic conditions such as high blood pressure and cholesterol, and at-home lab testing including STD, A1C, cholesterol and blood type tests. The platform combines clinical algorithms and decision-support tools with clinician review, and the company operates its own mail-order pharmacy that ships medicine the same day.
Lemonaid Health was acquired by consumer genetics company 23andMe in a transaction valued at $400 million, reported as roughly $100 million in cash and $300 million in 23andMe stock, completed in November 2021.
Founding story
Paul Johnson co-founded Lemonaid Health after moving from the UK to San Francisco in 2013, with a stated aim of increasing access to affordable, high-quality healthcare.
Business model
Direct-to-consumer telemedicine: patients pay out of pocket for online consultations and subscription-priced prescription treatments, with medication dispensed through the company's own mail-order pharmacy and shipped free to the patient. The company positions its care as costing less than typical insurance co-pays and has also begun working with partners inside the existing healthcare system to extend reach beyond pure direct-to-consumer distribution.
Consultation and treatment fees paid directly by patients, plus recurring monthly medication pricing; GLP-1 weight loss treatment has been promoted from $129 per month with free delivery, and no insurance is required.
Traction
The company reported having helped 1 million patients as of mid-2020, with a stated goal of reaching 10 million, and around 100 employees at that time including doctors, nurses, pharmacists, pharmacy technicians, patient support and operations staff, with plans to exceed 250 people by 2022. Demand for its services surged during the COVID-19 pandemic.
Latest developments
The consumer service continues to operate, with weight-loss GLP-1 treatments — compounded semaglutide and tirzepatide, tirzepatide microdosing and Zepbound vials — marketed alongside its mental health, men's and women's health, primary care and at-home testing lines, and promotional GLP-1 pricing from $129 per month.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positioned as a full-stack telehealth provider that owns both the virtual care encounter and the pharmacy fulfilment, differentiating it from telehealth services that only supply consultations. Its combination of prescription and delivery capability in a regulated market was cited as the strategic rationale for its acquisition by 23andMe, which had genetic testing data but no virtual care and prescription delivery channel.
Operating its own online pharmacy, offering lab testing through a partnership with Quest Diagnostics (an early investor) and at-home urine testing kits with Scanwell Health, and using clinical algorithms alongside licensed clinicians. The company reported an industry-leading Net Promoter Score of 89 for its medical team, website and mobile app.
Technology
A proprietary platform that integrates clinical algorithms and decision-support tools with clinician review, delivered via website and mobile app, connected to an in-house mail-order pharmacy and to lab testing partners; at-home urine testing kits are offered through a partnership with Scanwell Health.
Go-to-market
Direct-to-consumer online acquisition through its website and mobile app, promotional pricing offers and referral incentives, supported by brand marketing (including a 2020 brand overhaul with agency Squared Circles) and partnerships with other healthcare providers.
U.S. consumers seeking routine, chronic and elective care online without an in-person visit — including patients seeking weight-loss medication, mental health treatment, sexual and reproductive health, dermatology and common acute conditions.
Geography
United States nationwide, with a medical team licensed in all 50 states and headquarters in San Francisco, California. At the time of its 2017 Series A the service covered 10 states before expanding nationally; care modality varies by state because telemedicine regulations differ (video, telephone or secure messaging).
History
Founded by Paul Johnson, who served as co-founder and CEO. The company raised an $11 million Series A in 2017, when it operated in 10 states, and an oversubscribed $33 million Series B in July 2020 that brought total financing to $55 million and funded expansion into asthma, hypertension, Type 2 diabetes and additional mental health services. It engaged agency Squared Circles for a brand overhaul in 2020. In November 2021 it was sold to 23andMe for $400 million.
Risks & controversies
Telemedicine rules differ by state, restricting which consultation modalities the company can use in each jurisdiction. Third-party websites using the Lemonaid Health name and closely similar domains promote GLP-1 offers and testimonials that do not originate from the company's own site, which creates potential for consumer confusion.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
3 people who came through Lemonaid went on to found or lead other companies.
Timeline · 5
launches, deals, and filings23andMe acquired Lemonaid Health in a deal valued at $400 million, reportedly structured as approximately $100 million in cash and $300 million in 23andMe stock; the founder describes the sale as completed in November 2021 at over 10x the Series A price.
$400M source ↗
Lemonaid Health partnered with agency Squared Circles for a full brand overhaul following its Series B round.
With Series B proceeds the company expanded its medical team and added treatment for asthma, hypertension, Type 2 diabetes and more mental health services; reach expanded from 10 states at Series A to nationwide.
Oversubscribed Series B led by Olive Tree Ventures with Artis Ventures, Correlation Ventures, Hikma Ventures and Sierra Ventures participating; brings total financing to $55 million and funds expansion of the medical team and new services including asthma, hypertension, Type 2 diabetes and additional mental health care.
$33M source ↗
Lemonaid Health offers lab testing through a partnership with Quest Diagnostics, an early investor, and at-home urine testing kits through a partnership with Scanwell Health.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Lemonaidlemonaidhealth.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Lemonaid do?
- National U.S. telehealth company providing online medical assessments, prescriptions and mail-order medication delivery.
- Who founded Lemonaid?
- Lemonaid was founded by Paul Johnson.
- Who are Lemonaid's investors?
- Lemonaid's investors include Artis Ventures, Civilization Ventures Management, Llc, Correlation Ventures, Daybreak Partners, eGateway Capital, Firebolt Ventures Management Company, Llc, Hikma Ventures, OTV and 3 more.
- Who acquired Lemonaid?
- Lemonaid was acquired by 23andMe.
- Where is Lemonaid headquartered?
- Lemonaid is headquartered in San Francisco, US.